Biotech entity
Every one of those 1 sits in a single category, fda-approval. Opdivo (nivolumab) is most often covered alongside Bristol Myers Squibb, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Opdivo (nivolumab), all published on August 20, 2026.
Last mentioned: 3d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, fda-approval. Opdivo (nivolumab) is most often covered alongside Bristol Myers Squibb, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Opdivo (nivolumab), all published on August 20, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Opdivo (nivolumab). Shared-story counts are live from our verified record — not editorial picks.
Biopharma companies face a growing dose-optimization debate as researchers present evidence that checkpoint inhibitors such as Opdivo and Keytruda can be effective at fractions of FDA-approved doses. Regulatory and commercial models built on fixed dosing face pressure to incorporate dose-ranging data.
Source: edition.cnn.com · freerepublic.com
Opdivo (nivolumab) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
